This finding contrasts with studies in pancreatic cancers25 and likely results from lack of power to detect a survival difference; only 5 patients were identified with a BRCA1/2 variant with metastatic esophagogastric adenocarcinoma who received first-line platinum-based therapy (other patients were anonymized or had squamous cell carcinoma tumors or locally advanced disease). Here, BRCA1 is linked to gastroesophageal junction adenocarcinoma.